Arjmand Parisa, Bahrami Milad, Mohammadie Zahra Eslami, Taherynejad Mohammadhossein, Khorasani Negar Yeganeh, Mehrad-Majd Hassan, Roshanzamir Imaneh, Bakhshaee Mehdi
Department of Otorhinolaryngology, Ghaem Hospital Mashhad University of Medical Sciences Mashhad Iran.
Department of Laboratory Sciences, Faculty of Paramedical Sciences Mashhad University of Medical Sciences Mashhad Iran.
Laryngoscope Investig Otolaryngol. 2022 Sep 7;7(5):1343-50. doi: 10.1002/lio2.899.
Mucormycosis is a rare yet devastating fungal disease with a frequently fatal outcome. The purpose of this study was to compare the prevalence of mucormycosis, evaluate its risk factors, and assess the patients' outcomes in pre-COVID-19 and COVID-19 era.
In this retrospective observational study, clinical data of 158 patients with confirmed histopathological diagnosis of mucormycosis were collected from the medical records departments of Imam Reza and Ghaem hospitals, Mashhad, Iran during 2018-2021. The collected data were risk factors associated with mucormycosis including age, gender, underlying diseases, details of corticosteroid administration, and complications such as blindness and mortality.
Of 158 studied patients, 48 patients were diagnosed in the pre-pandemic period whereas 110 cases were admitted during the pandemic era. COVID-19 associated mucormycosis (CAM) was observed in 58.1% of the pandemic cases. In the pre-pandemic period, cancer (89.5% vs. 39%, < .001) was significantly more prevalent while during the pandemic era, the prevalence of diabetes mellitus (16.7% vs. 51%, < .001) was remarkably higher. Moreover, the mortality rate of mucormycosis was considerably reduced after the pandemic (64.6%-45.4%), especially in CAM patients (35.9%).
The COVID-19 pandemic has led to an increased prevalence of mucormycosis, due to the convergence of interlinked risk factors such as diabetes mellitus, corticosteroid therapy, and COVID-19. Therefore, clinicians must be aware of the probable occurrence of mucormycosis in the first or second week of COVID-19 infection in vulnerable patients and use the steroids cautiously.
4 Laryngoscope Investigative Otolaryngology, 2022.
毛霉病是一种罕见但具有毁灭性的真菌疾病，往往会导致致命后果。本研究旨在比较毛霉病的患病率，评估其危险因素，并评估新冠疫情前和疫情期间患者的治疗结果。
在这项回顾性观察研究中，2018年至2021年期间从伊朗马什哈德伊玛目礼萨医院和加姆医院的病历部门收集了158例经组织病理学确诊为毛霉病患者的临床数据。收集的数据包括与毛霉病相关的危险因素，如年龄、性别、基础疾病、糖皮质激素使用细节以及失明和死亡等并发症。
在158例研究患者中，48例在疫情前被诊断出，而110例在疫情期间入院。在疫情期间的病例中，58.1%观察到新冠相关毛霉病（CAM）。在疫情前，癌症（89.5%对39%，<0.001）的患病率显著更高，而在疫情期间，糖尿病的患病率（16.7%对51%，<0.001）明显更高。此外，疫情后毛霉病的死亡率大幅降低（64.6%-45.4%），尤其是CAM患者（35.9%）。
由于糖尿病、糖皮质激素治疗和新冠等相互关联的危险因素的共同作用，新冠疫情导致毛霉病的患病率增加。因此，临床医生必须意识到在新冠感染的第一周或第二周，易感患者可能发生毛霉病，并谨慎使用类固醇。
4 喉镜研究性耳鼻喉科，2022年
